Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.68 |
| ▸ | CTSS | P25774 | 3/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | ECE1 | P42892 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22960914 | 0.92 | CTSK (0.64) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL28778606 | 0.92 | CTSK (0.64) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL16909078 | 0.87 | CTSS (0.70) | CTSKCTSSCA2CTSLCTSB | |
| SCHEMBL16921307 | 0.87 | CTSS (0.70) | CTSKCTSSCA2CTSLCTSB | |
| SCHEMBL1003572 | 0.85 | CTSK (0.71) | CTSKCTSSCA2ECE1CA1 | |
| SCHEMBL2116924 | 0.85 | CTSK (0.71) | CTSKCTSSCA2ECE1CA1 | |
| SCHEMBL5559974 | 0.85 | CTSK (0.67) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL7290917 | 0.85 | KMT2A (0.54) | CTSKCTSSCA2ECE1CA1 | |
| SCHEMBL28969869 | 0.85 | CTSK (0.67) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL7058987 | 0.85 | KMT2A (0.54) | CTSKCTSSCA2ECE1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011033296-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | CTSK 3162/4885CTSS 2203/4885CA2 2675/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | CTSK 3162/4885CTSS 2203/4885CA2 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.